Newsfeeds Archive - Page 3 of 3

1 minute read

Credit Suisse Initiates Coverage On Mineralys Therapeutics with Outperform Rating, Announces Price Target of $40

March 7, 8:13 AM

Credit Suisse analyst Richard Law initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Outperform rating and announces Price Target of $40.

MLYS

1 minute read

Guggenheim Initiates Coverage On Mineralys Therapeutics with Buy Rating, Announces Price Target of $32

By Benzinga Newsdesk

March 7, 8:10 AM

Guggenheim analyst Seamus Fernandez initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $32.

MLYS

1 minute read

B of A Securities Initiates Coverage On Mineralys Therapeutics with Buy Rating, Announces Price Target of $39

By Benzinga Newsdesk

March 7, 8:09 AM

B of A Securities analyst Greg Harrison initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $39.

MLYS

1 minute read

Stifel Initiates Coverage On Mineralys Therapeutics with Buy Rating, Announces Price Target of $45

By Benzinga Newsdesk

March 7, 6:20 AM

Stifel analyst Annabel Samimy initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $45.

MLYS

1 minute read

Mineralys Therapeutics Announced Lorundrostat Demonstrated Clinically Meaningful Blood Pressure Reduction In Individuals With Uncontrolled Hypertension

By Charles Gross

March 4, 5:41 PM

Mineralys Therapeutics, Inc.

MLYS

2 minute read

Around $11M Bet On Insight Enterprises? Check Out These 4 Stocks Insiders Are Buying

By Lisa Levin

February 17, 8:58 AM

Although US stocks closed lower on Thursday, there were a few notable insider trades.

BHM

3 minute read

Options

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

February 13, 12:24 PM

On Monday, 42 companies hit new 52-week lows.

ALLR

1 minute read

Reported Late Thursday Feb 9, Mineralys Therapeutics Announces Pricing Of $192M Upsized Initial Public Offering Of 12M Shares Of Common Stock At A Price Of $16/Share

By Happy Mohamed

February 10, 1:10 AM

Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone, today announced the pricing of its

MLYS